Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPRC | P08575 | 1/20 | 0.43 |
| ▸ | CDC25B | P30305 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | PABPC1 | P11940 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.33 |
| ▸ | NQO1 | P15559 | 1/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
| ▸ | ELANE | P08246 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | CA12 | O43570 | 1/20 | 0.30 |
| ▸ | CA1 | P00915 | 1/20 | 0.30 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.30 |
| ▸ | CA4 | P22748 | 1/20 | 0.30 |
| ▸ | CA6 | P23280 | 1/20 | 0.30 |
| ▸ | CA5A | P35218 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15672207 | 0.83 | CYP2A6 (0.36) | PTPRCCDC25BKDM4EMEN1MAPT | |
| SCHEMBL8598340 | 0.75 | PTPN1 (0.38) | ALDH1A1CA12CA1CA9 | |
| SCHEMBL15672211 | 0.75 | PTPN1 (0.31) | — | |
| SCHEMBL2961774 | 0.75 | — | — | |
| SCHEMBL6566935 | 0.74 | — | — | |
| SCHEMBL8905991 | 0.74 | PTPRC (0.47) | PTPRCKDM4EMEN1MAPTKMT2A | |
| SCHEMBL15672436 | 0.74 | MAPT (0.33) | KDM4EMEN1MAPTKMT2AALDH1A1 | |
| SCHEMBL15672222 | 0.74 | APP (0.33) | KDM4EALDH1A1 | |
| SCHEMBL15672208 | 0.74 | APP (0.33) | KDM4EALDH1A1 | |
| SCHEMBL9794644 | 0.72 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-1991016189-A1 | POLYMER GRAFTING PROCESS, APPARATUS AND PRODUCTS OBTAINED THEREWITH | EXXON CHEMICAL PATENTS INC. (US) | 1991-10-31 | — | — | WO | claimed |
| US-9786952-B2 | Lithium secondary cell including an electrolytic solution including cyclic acid anhydrides | NEC CORPORATION (JP) | 2017-10-10 | — | — | US | disclosed |
| US-9701667-B2 | Coumarin-based fluorogenic agents and uses thereof for specific protein labelling | UNIVERSITY OF OTTAWA (CA) | 2017-07-11 | — | — | US | disclosed |
| US-9701667-B2 | Coumarin-based fluorogenic agents and uses thereof for specific protein labelling | UNIVERSITY OF OTTAWA (CA) | 2017-07-11 | — | — | US | disclosed |
| US-20150316557-A1 | COUMARIN-BASED FLUOROGENIC AGENTS AND USES THEREOF FOR SPECIFIC PROTEIN LABELLING | UNIVERSITY OF OTTAWA (CA) | 2015-11-05 | — | — | US | disclosed |
| US-20150316557-A1 | COUMARIN-BASED FLUOROGENIC AGENTS AND USES THEREOF FOR SPECIFIC PROTEIN LABELLING | UNIVERSITY OF OTTAWA (CA) | 2015-11-05 | — | — | US | disclosed |
| US-20140120415-A1 | LITHIUM SECONDARY CELL | NEC CORPORATION (JP) | 2014-05-01 | — | — | US | disclosed |
| US-7161022-B2 | Process for producing 4-phenyl-4-oxo-2-butenoic ester derivative | FUJIFILM FINECHEMICALS CO., LTD. (JP) | 2007-01-09 | — | — | US | disclosed |
| US-7161022-B2 | Process for producing 4-phenyl-4-oxo-2-butenoic ester derivative | FUJIFILM FINECHEMICALS CO., LTD. (JP) | 2007-01-09 | — | — | US | disclosed |
| WO-1991016189-A1 | POLYMER GRAFTING PROCESS, APPARATUS AND PRODUCTS OBTAINED THEREWITH | EXXON CHEMICAL PATENTS INC. (US) | 1991-10-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150316557-A1 | COUMARIN-BASED FLUOROGENIC AGENTS AND USES THEREOF FOR SPECIFIC PROTEIN LABELLING | PFDN1, PFDN6, CDC73 | PTPRC 3282/4885CDC25B 2677/4885KDM4E 3817/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.